Treatment Information

Back

Melanoma treatment details. Chemotherapy.

Saint John's Health Center, Santa Monica, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Santa Monica, CA
Treatments:ChemotherapyHospital:Saint John's Health Center
Drugs:Journal:Link
Date:Jan 2012

Description:

Patients:
This phase II study involved previously untreated metastatic melanoma patients who were divided into two separate treatment groups. Group A consisted of 71 patients with a median age of 60 years and 70.4% male. Group B had 143 patients with a median age of 60 years and 68.5% male.

Treatment:
Patients in group A were treated with the chemotherapy agents paclitaxel and carboplatin.

Patients in group B were treated with paclitaxel, carboplatin, and the biologic therapy agent bevacizumab.

Toxicities:
The most severe toxicities reported for group A were grade 3-4 neutropenia and hemorrhage.

There were 2 deaths possibly related to treatment in group B. Grade 3-4 peripheral neuropathy (nerve disorder), high blood pressure, and neutropenia were also reported.

Results:
The median overall survival rate for groups A and B was 8.6 and 12.3 months, respectively.

Support:
This study was supported by Genentech, makers of bevacizumab.

Correspondence: Dr. Steven J. O’Day; email: [email protected]



Back